Cannabinoid

Cronos Group and Ginkgo Bioworks have achieved the first target productivity milestone in their partnership to produce eight cultured cannabinoids.   Using Ginkgo’s platform for organism design and development, Cronos Group has successfully achieved the productivity target for cannabigerolic acid (CBGA), which will support Cronos Group’s planned CBG product launch this fall.   Launched in 2018 with the goal of accessing […]

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved a new indication for GW Pharmaceutical’s cannabidiol as an adjunctive treatment of seizures associated with tuberous sclerosis complex (TSC), for patients two years of age and older. GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with […]

Botanical Holdings was founded in early 2020 with a focus on investing within the legal cannabis sector. There is now a substantial body of evidence to support the effectiveness of cannabis-based medicines in treating a range of conditions from epilepsy to chronic pain. More recently, attention has also turned to the potential of certain psychedelic […]

Oxford Cannabinoid Technologies (OCTP) and Evotec have entered into a service agreement to expedite the development of OCTP’s lead compound, OCT461201, a selective cannabinoid receptor Type 2 agonist, towards Phase I clinical trials. This Phase I clinical trial will be aimed at demonstrating the safety and tolerability of the drug product. OCT461201 will enter Evotec’s […]